From the moment their toddler, Eytani, was diagnosed with Duchenne muscular dystrophy in 2012, Ilan Ganot and his wife, Annie, have lived with a death sentence.
Because DMD is rare — affecting about 300,000 people worldwide — potential treatments tend to languish in the lab for lack of funding.
Ilan Ganot doesn’t know medicine, but he does know finance, so he quit his job at J.P. Morgan and founded a for-profit company, Solid Ventures, aggressively devoted to identifying, acquiring and developing therapies for the genetic disorder that causes this fatal muscle degeneration.
“Progress is always going to be too slow for me because my son’s life is on the line,” the former Israel Defense Forces officer and Tel Aviv corporate lawyer said from his home outside Boston. Eytani is now 4, and people with DMD often don’t make it past their 20s.
“Solid was born out of necessity and mission. This is not a charity,” Ganot emphasized. “Real investment and real effort hasn’t been directed sufficiently toward the type of solutions that could be offered. We’re coming with money and passion, and we know what to do.”
Reprinted with permission from Israel21c, www.israel21c.org